SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The… Read more
SMS Pharmaceuticals Limited (SMSPHARMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.058x
Based on the latest financial reports, SMS Pharmaceuticals Limited (SMSPHARMA) has a cash flow conversion efficiency ratio of 0.058x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹423.25 Million) by net assets (₹7.29 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SMS Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how SMS Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SMS Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SMS Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DUOL34
SA:DUOL34
|
0.215x |
|
EUROCELL (WI) LS -001
F:6YQ
|
N/A |
|
Namchow Chemical Industrial Co Ltd
TW:1702
|
-0.027x |
|
Enwei Pharmaceutical Co. Ltd. A
SHE:301331
|
N/A |
|
KOGENERACJA S.A. ZY 5
F:2ZO
|
N/A |
|
TrueBlue Inc
NYSE:TBI
|
-0.176x |
|
SMARTOPTICS GRP AS NK-02
F:3YL
|
N/A |
|
Meteoric Resources NL
OTCGREY:METOF
|
N/A |
Annual Cash Flow Conversion Efficiency for SMS Pharmaceuticals Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of SMS Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹6.40 Billion | ₹645.23 Million | 0.101x | +7.93% |
| 2024-03-31 | ₹5.36 Billion | ₹501.25 Million | 0.093x | +91.72% |
| 2023-03-31 | ₹4.61 Billion | ₹224.50 Million | 0.049x | -43.02% |
| 2022-03-31 | ₹4.70 Billion | ₹402.34 Million | 0.086x | -61.17% |
| 2021-03-31 | ₹4.11 Billion | ₹904.53 Million | 0.220x | +93.21% |
| 2020-03-31 | ₹3.48 Billion | ₹397.12 Million | 0.114x | -26.22% |
| 2019-03-31 | ₹3.22 Billion | ₹497.57 Million | 0.155x | +38.21% |
| 2018-03-31 | ₹2.84 Billion | ₹318.15 Million | 0.112x | -60.25% |
| 2017-03-31 | ₹3.35 Billion | ₹941.46 Million | 0.281x | +34.93% |
| 2016-03-31 | ₹2.94 Billion | ₹612.20 Million | 0.209x | -32.71% |
| 2015-03-31 | ₹2.55 Billion | ₹789.42 Million | 0.310x | +5.60% |
| 2014-03-31 | ₹2.22 Billion | ₹650.85 Million | 0.293x | +308.46% |
| 2013-03-31 | ₹2.44 Billion | ₹-343.56 Million | -0.141x | -257.05% |
| 2012-03-31 | ₹2.21 Billion | ₹198.16 Million | 0.090x | +35.08% |
| 2011-03-31 | ₹2.20 Billion | ₹145.94 Million | 0.066x | -43.91% |
| 2010-03-31 | ₹2.13 Billion | ₹252.46 Million | 0.118x | +20.03% |
| 2009-03-31 | ₹2.12 Billion | ₹209.12 Million | 0.099x | +293.88% |
| 2008-03-31 | ₹2.08 Billion | ₹52.10 Million | 0.025x | -45.53% |
| 2007-03-31 | ₹1.83 Billion | ₹83.96 Million | 0.046x | -56.99% |
| 2006-03-31 | ₹556.25 Million | ₹59.42 Million | 0.107x | -28.59% |
| 2005-03-31 | ₹480.53 Million | ₹71.89 Million | 0.150x | -- |